TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06735248: A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

Sponsor: ModernaTX, Inc. · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 180 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$2,328,000

Rescue Site Savings

+$1,552,000

Unlock Full NCT06735248 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06735248 Rescue Dossier →